Detalles del proyecto
| Estado | Finalizado |
|---|---|
| Fecha de inicio/Fecha fin | 10/1/19 → 2/21/22 |
Financiación
- Nektar Therapeutics: 114.398,00 US$
A Phase 1/2, Open-label, Multicenter Study of the Combination of Nktr-214 and Nivolumab or the Combination of Nktr-214, Nivolumab, and Other Anti-cancer Therapies in Patients With Select Locally Advanced or Metastatic Solid Tumor Malignancies
- Arnold, Susanne M (PI)